tumorsMalignant tumoursMalignant tumours2224-50572587-6813Rosoncoweb10.18027/2224-5057-2022-12-3s1-39-42tumors-998Research ArticleСтатьиБессимптомные метастазы в кости при раке молочной железы. «Лечить нельзя наблюдать» — где можно поставить запятую?БагроваС. Г.

Москва

s.bagrova@mail.ruФГБУ «НМИЦ онкологии им. Н. Н. Блохина» Минздрава РоссииRussian Federation202218112022123s13942Copyright © Багрова С.Г., 20222022Багрова С.Г.Багрова С.Г.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.malignanttumors.org/jour/article/view/998

Метастатическое поражение костей при раке молочной железы является актуальной проблемой. Большинству пациентов показано назначение остеомодифицирующей терапии. В статье определен портрет пациентки, для которой применение антирезорбтивных средств может быть отложено или отменено.

метастазы в костяхостеомодифицирующие агентыантирезорбтивная терапиябисфосфонатызоледроновая кислотаденосумабReferencesБагрова С. Г., Басин Е. М., Валиев А. К., Деньгина Н. В., Копп М. В., Кутукова С. И. и соавт. Профилактика и лечение патологии костной ткани при злокачественных новообразованиях. Злокачественные опухоли : Практические рекомендации RUSSCO #3s2, 2021 (том 11). 38.Багрова С. Г., Басин Е. М., Валиев А. К., Деньгина Н. В., Копп М. В., Кутукова С. И. и соавт. Профилактика и лечение патологии костной ткани при злокачественных новообразованиях. Злокачественные опухоли : Практические рекомендации RUSSCO #3s2, 2021 (том 11). 38.von Moos R. Costa L. Gonzalez-Suarez E. et al. Management of bone health in solid tumours : from bisphosphonates to a monoclonal antibody. Cancer Treat Rev. 2019 ; 76 : 57–67.von Moos R. Costa L. Gonzalez-Suarez E. et al. Management of bone health in solid tumours : from bisphosphonates to a monoclonal antibody. Cancer Treat Rev. 2019 ; 76 : 57–67.Coleman R, et al. Bone health in cancer : ESMO Clinical Practice Guidelines. Ann Oncol 2020 : S0923–7534 (20) 39995–6.Coleman R, et al. Bone health in cancer : ESMO Clinical Practice Guidelines. Ann Oncol 2020 : S0923–7534 (20) 39995–6.NCCN Guidelines Version 1.2022. Adult Cancer Pain / https://www.nccn.org/guidelines/guidelines-detail?category=3&id=1413.NCCN Guidelines Version 1.2022. Adult Cancer Pain / https://www.nccn.org/guidelines/guidelines-detail?category=3&id=1413.O’Carrigan B, Wong MH, Willson ML, et al : Bisphosphonates and other bone agents for breast cancer. Cochrane Database Syst Rev 10 : CD003474, 2017. 42O’Carrigan B, Wong MH, Willson ML, et al : Bisphosphonates and other bone agents for breast cancer. Cochrane Database Syst Rev 10 : CD003474, 2017. 42Roger von Moosa, Jean-Jacques Bodyb, Alex Riderc et al. Bone-targeted agent treatment patterns and the impact of bone metastases on patients with advanced breast cancer in real-world practice in six European countries. Journal of Bone Oncology 11 (2018) 1–9.Roger von Moosa, Jean-Jacques Bodyb, Alex Riderc et al. Bone-targeted agent treatment patterns and the impact of bone metastases on patients with advanced breast cancer in real-world practice in six European countries. Journal of Bone Oncology 11 (2018) 1–9.Guy Hechmati, A. Brett Hauber et al. Patients’ preferences for bone metastases treatments in France, Germany and the United Kingdom. Supportive Care in Cancer 2323, pages21–28 (2015).Guy Hechmati, A. Brett Hauber et al. Patients’ preferences for bone metastases treatments in France, Germany and the United Kingdom. Supportive Care in Cancer 2323, pages21–28 (2015).Wang X, Yang KH, Wanyan P, Tian JH : Comparison of the efficacy and safety of denosumab versus bisphosphonates in breast cancer and bone metastases treatment : A meta-analysis of randomized controlled trials. Oncol Lett 7 : 2014.Wang X, Yang KH, Wanyan P, Tian JH : Comparison of the efficacy and safety of denosumab versus bisphosphonates in breast cancer and bone metastases treatment : A meta-analysis of randomized controlled trials. Oncol Lett 7 : 2014.Henry D, Vadhan-Raj S, Hirsh V, et al : Delaying skeletal-related events in a randomized phase 3 study of denosumab versus zoledronic acid in patients with advanced cancer : An analysis of 2017 data from patients with solid tumors. Support Care Cancer 22 : 679, 2014.Henry D, Vadhan-Raj S, Hirsh V, et al : Delaying skeletal-related events in a randomized phase 3 study of denosumab versus zoledronic acid in patients with advanced cancer : An analysis of 2017 data from patients with solid tumors. Support Care Cancer 22 : 679, 2014.Otto S., Pautke C., Van den Wyngaert T. et al. Medication-related osteonecrosis of the jaw : prevention, diagnosis and management in patients with cancer and bone metastases. Cancer Treat Rev. 2018; 69 : 177–187.Otto S., Pautke C., Van den Wyngaert T. et al. Medication-related osteonecrosis of the jaw : prevention, diagnosis and management in patients with cancer and bone metastases. Cancer Treat Rev. 2018; 69 : 177–187.Tanda N, Tada H, Washio J, Takahashi N, Ishida T, Koseki T (2022) Influence of alcohol sensitivity on bone metastases and skeletal-related events in primary operable breast cancer : A retrospective cohort study. PLOS ONE | https://doi.org/10.1371/journal.pone.0269335/ June 3, 2022Tanda N, Tada H, Washio J, Takahashi N, Ishida T, Koseki T (2022) Influence of alcohol sensitivity on bone metastases and skeletal-related events in primary operable breast cancer : A retrospective cohort study. PLOS ONE | https://doi.org/10.1371/journal.pone.0269335/ June 3, 2022

The authors declare that there are no conflicts of interest present.